烟台东诚药业集团股份有限公司2025年半年度报告摘要

Core Points - The company, Yantai Dongcheng Pharmaceutical Group Co., Ltd., held its 12th meeting of the 6th Board of Directors on August 14, 2025, to review the 2025 semi-annual report [8][10] - The Board of Directors unanimously approved the semi-annual report and its summary, confirming that the report accurately reflects the company's actual situation without any false records or misleading statements [12][9] - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [3][4] Company Overview - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5][6] - All directors attended the board meeting, and the meeting was conducted in accordance with relevant laws and the company's articles of association [2][8] Financial Information - The semi-annual report and its summary are available for detailed review in designated media and on the company's official website [8][12] - The company has no preferred shareholders or related bond issues during the reporting period [7][4]